Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 27.26 CNY [3][7]. Core Views - The company is expected to experience a recovery starting in 2025, driven by strategic reforms and a new management team [6]. - The introduction of an equity incentive plan aims to motivate key personnel and align their interests with the company's performance [6]. - The company anticipates a double-digit revenue growth in 2025 following a challenging 2024 [6]. Financial Performance Summary - Revenue for 2023 was 6,598 million CNY, with a projected decline to 5,679 million CNY in 2024, followed by a recovery to 6,272 million CNY in 2025, representing a 10.4% growth [3][10]. - The net profit attributable to the parent company is expected to recover from a loss of 833 million CNY in 2024 to a profit of 321 million CNY in 2025, reflecting a 138.6% increase [3][10]. - Earnings per share (EPS) are projected to be 0.48 CNY in 2025, 0.69 CNY in 2026, and 0.89 CNY in 2027 [3][7]. Product and Channel Performance - In 2024, revenue from personal care, beauty, innovation, and overseas businesses is expected to decline by 3.4%, 29.8%, 19.4%, and 11.4% respectively, indicating pressure on the beauty segment [6]. - Online and offline revenue is projected to decrease by 9.7% and 17% respectively in 2024 [6]. Margin Analysis - The gross margin is expected to decline to 57.6% in 2024, with personal care showing a slight increase while beauty and overseas segments face declines [6]. - The net profit margin is projected to be -14.7% in 2024, reflecting significant challenges [6]. Strategic Initiatives - The company is focusing on online transformation and strategic adjustments in offline channels to adapt to industry changes [6]. - The management aims to enhance online operational capabilities, particularly in interest e-commerce and emerging platforms [6].

主业稳健，AI 赋能+出海增量可期 ——值得买 24 年年报及 25 年一季报点评 核心观点 盈利预测与投资建议 ⚫ 根据最新财报，我们预测公司 25-27 年归母净利润 1.3/1.5/1.8 亿元（原预测 25-26 年 归母净利润 1.4/1.7 亿元，根据最新财报下调收入预测和毛利率，AIGC 业务赋能下 调费用率），参考可比公司给予 25 年 60xPE（调整后均值），对应目标价 38.40 元/ 股，维持"买入"评级。 风险提示 行业竞争加剧，流量增长放缓，AIGC 进展不及预期对公司估值有所影响。 公司主要财务信息 | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 1,452 | 1,518 | 1,704 | 1,925 | 2,322 | | 同比增长 (%) | 18.2% | 4.5% | 12.3% | 13.0% | 20.6% | | 营业利润(百万元) | 83 | 83 | 159 | 183 | 228 | | 同比增长 (%) | - ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 59.21 CNY based on a 31x PE valuation for 2025 [2][5]. Core Insights - The company has shown strong performance with a projected revenue growth of 38.0% in 2025, reaching 4.202 billion CNY, and a net profit growth of 87.1%, amounting to 1.15 billion CNY [4][9]. - The domestic formulation business is experiencing rapid growth driven by both volume and price increases, with Q1 2025 domestic revenue reaching 8.6 billion CNY, up 80.9% year-on-year [9]. - The company is advancing its innovative product pipeline, with significant progress in international markets, including successful clinical trials and product launches [9]. Financial Performance Summary - **Revenue Forecast**: - 2023: 2.608 billion CNY - 2024: 3.045 billion CNY (growth of 16.8%) - 2025: 4.202 billion CNY (growth of 38.0%) - 2026: 5.181 billion CNY (growth of 23.3%) - 2027: 6.115 billion CNY (growth of 18.0%) [4][11] - **Net Profit Forecast**: - 2023: 340 million CNY - 2024: 615 million CNY (growth of 80.7%) - 2025: 1.15 billion CNY (growth of 87.1%) - 2026: 1.445 billion CNY (growth of 25.6%) - 2027: 1.709 billion CNY (growth of 18.3%) [4][11] - **Earnings Per Share (EPS)**: - 2023: 0.57 CNY - 2024: 1.02 CNY - 2025: 1.91 CNY - 2026: 2.40 CNY - 2027: 2.84 CNY [4][11] - **Profitability Ratios**: - Gross Margin: Expected to increase from 73.3% in 2023 to 78.7% in 2025 - Net Margin: Expected to rise from 13.0% in 2023 to 27.4% in 2025 [4][11] - **Valuation Ratios**: - PE Ratio: Expected to decrease from 90.1 in 2023 to 26.7 in 2025 - PB Ratio: Expected to decrease from 2.9 in 2023 to 2.5 in 2025 [4][11]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company is expected to achieve earnings per share of 1.91, 2.40, and 2.84 yuan for the years 2025, 2026, and 2027 respectively, with a target price of 59.21 yuan based on a 31x PE valuation for 2025 [2] - The company reported a revenue of 30.5 billion yuan in 2024, representing a year-on-year growth of 16.8%, and a net profit of 6.1 billion yuan, up 80.8% [10] - The company’s Q1 2025 revenue reached 9.8 billion yuan, a significant increase of 75.8%, with a net profit of 3.1 billion yuan, reflecting a remarkable growth of 224.9% [10] - The domestic formulation business is experiencing rapid growth driven by both volume and price increases, with domestic formulation revenue in Q1 2025 at 8.6 billion yuan, up 80.9% [10] - The company’s international sales revenue in Q1 2025 was 0.95 billion yuan, an increase of 45.2%, indicating strong overseas order growth [10] - The company has made progress in its innovative product pipeline, with ongoing clinical trials for its new drug GZR18 and successful entry into international markets for its insulin products [10] Financial Information Summary - Revenue projections for the company are as follows: 2,608 million yuan in 2023, 3,045 million yuan in 2024, 4,202 million yuan in 2025, 5,181 million yuan in 2026, and 6,115 million yuan in 2027, with respective growth rates of 52.3%, 16.8%, 38.0%, 23.3%, and 18.0% [4] - The company's net profit is projected to grow from 340 million yuan in 2023 to 1,709 million yuan in 2027, with growth rates of 177.4%, 80.7%, 87.1%, 25.6%, and 18.3% [4] - The gross margin is expected to improve from 73.3% in 2023 to 75.8% in 2027, while the net margin is projected to increase from 13.0% to 27.9% over the same period [4] - The company’s PE ratio is forecasted to decrease from 90.1 in 2023 to 17.9 in 2027, indicating an improving valuation [4]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 11.56 CNY based on a 34x P/E ratio for 2025 [4][7]. Core Views - The company has experienced significant growth in diaphragm production and sales, with a year-on-year increase of 56.3% in production and 57.6% in sales for 2024 [10]. - Despite the growth in production and sales, the company's profitability is under pressure due to declining diaphragm prices, leading to a forecasted decrease in earnings per share for 2025 and 2026 [4][10]. - The company is actively expanding its global footprint, with ongoing construction of overseas bases in Malaysia and Sweden, which is expected to enhance local supply capabilities [10]. - The company is investing in new product development to meet the trends in battery technology, including the production of new coated diaphragm products and collaborations for solid-state electrolyte membranes [10]. Financial Summary - The company’s revenue is projected to grow from 30.13 billion CNY in 2023 to 77.20 billion CNY in 2027, with a compound annual growth rate (CAGR) of approximately 30.2% [6]. - The net profit attributable to the parent company is expected to recover from 3.64 billion CNY in 2024 to 10.74 billion CNY in 2027, reflecting a significant growth trajectory [6]. - The gross margin is forecasted to improve from 29.1% in 2024 to 37.4% in 2027, indicating a recovery in profitability as market conditions stabilize [6].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 38.40 CNY per share, based on a 60x PE ratio for 2025 [2][4]. Core Insights - The company's main business remains stable, with potential growth driven by AI empowerment and overseas expansion. The financial performance shows a gradual recovery, with a focus on AIGC applications [1][7]. - The company achieved a revenue of 1.52 billion CNY in 2024, reflecting a year-on-year growth of 4.55%, and a net profit of 75 million CNY, up 0.62% year-on-year [7]. - The "What Worth Buying" app's monthly active users (MAU) reached 3967.8 million in 2024, a 1.0% increase year-on-year, with significant growth in AIGC content generation [7]. Financial Summary - Revenue projections for 2025-2027 are 1.704 billion CNY, 1.925 billion CNY, and 2.322 billion CNY, respectively, with year-on-year growth rates of 12.3%, 13.0%, and 20.6% [3][10]. - The company's net profit is forecasted to be 127 million CNY in 2025, 145 million CNY in 2026, and 181 million CNY in 2027, with growth rates of 68.4%, 14.7%, and 24.8% respectively [3][10]. - The gross margin is expected to be around 46.9% in 2025, with a net margin of 7.4% [3][10]. Business Development - The company is expanding its new business segments, with operational service revenue projected to reach 327 million CNY in 2024, a 17.29% increase year-on-year [7]. - The overseas revenue for 2024 is expected to be 4.807 million CNY, showing a year-on-year growth of 19.9% [7].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 11.56 CNY based on a 34x P/E ratio for 2025 [4][7]. Core Views - The company has experienced significant growth in diaphragm production and sales, with a year-on-year increase of 56.3% in production and 57.6% in sales for 2024 [10]. - Despite the high growth in production and sales, the company's profitability is under pressure due to declining diaphragm prices, leading to a forecasted decrease in earnings per share for 2025 and 2026 [4][10]. - The company is actively expanding its global footprint, with ongoing construction of overseas bases in Malaysia and Sweden, which are expected to enhance local supply capabilities [10]. - The company is investing in new product development to align with trends in battery technology, including the production of new coated diaphragm products and collaborations for solid-state electrolyte membranes [10]. Financial Summary - The company’s revenue is projected to grow from 30.13 billion CNY in 2023 to 77.20 billion CNY in 2027, reflecting a compound annual growth rate (CAGR) of approximately 30.2% [6]. - The net profit attributable to the parent company is expected to recover from 3.64 billion CNY in 2024 to 10.74 billion CNY in 2027, with a notable increase of 57.1% in 2026 [6]. - The gross margin is forecasted to improve from 29.1% in 2024 to 37.4% in 2027, indicating a recovery in profitability as diaphragm prices stabilize [6].

Export Performance - In April 2025, exports increased by 8.1% year-on-year, down from 12.4% in the previous month[3] - Traditional consumer goods exports showed a decline, with footwear, toys, luggage, and clothing down by -8.6%, -5.4%, -12.7%, and -1.5% respectively[5] - Mechanical and electrical products exports performed well, with a year-on-year growth of 8.3% in April 2025[5] Import Trends - Imports decreased by -0.2% year-on-year, a significant improvement from -4.3% in the previous month[3] - The decline in imports was narrowed by increased purchases of bulk commodities like soybeans and copper ore[5] - The import growth rate for certain mechanical and electrical products also increased[5] Trade Dynamics - Exports to ASEAN countries saw a remarkable increase of 20.8% year-on-year, while exports to the US fell sharply by -21%[5] - The proportion of tariff exemptions for exports to the US was approximately 27.1%, with 22.8% being tariff exemptions on electronics[5] - Indirect trade channels have shown resilience, with a potential offsetting ratio of 44.5% to 90% for trade losses with the US[5]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 8.5 CNY based on a 17x PE valuation for 2025 [2][4][9]. Core Insights - The company has shown resilience in its Q1 performance, with a revenue of 20,957 million CNY in 2024, reflecting a 2.7% year-on-year decline, while the net profit attributable to the parent company decreased by 26.9% to 2,159 million CNY [8]. - The company is focusing on new business growth points, particularly in the sports sector, and has made strategic investments to enhance its market presence [8]. - The financial forecasts for 2025-2027 indicate an expected EPS of 0.50, 0.56, and 0.63 CNY respectively, with revenue growth projected at 7.3%, 9.0%, and 8.8% [2][9]. Financial Performance Summary - The company's revenue for 2023 was 21,528 million CNY, with a year-on-year growth of 16.0%. The projected revenues for 2024, 2025, 2026, and 2027 are 20,957 million CNY, 22,496 million CNY, 24,511 million CNY, and 26,671 million CNY respectively [2][12]. - The operating profit for 2023 was 3,611 million CNY, with a growth of 28.7%. The expected operating profits for the next few years are 2,780 million CNY, 3,039 million CNY, 3,360 million CNY, and 3,790 million CNY [2][12]. - The net profit attributable to the parent company for 2023 was 2,952 million CNY, with a growth of 37.0%. The forecasts for the following years are 2,159 million CNY, 2,417 million CNY, 2,667 million CNY, and 3,003 million CNY [2][12]. Market Position and Strategy - The company is actively expanding its online and offline channels, with online revenue growth of 35.6% in 2024, while offline channels grew by 10% [8]. - The company is also focusing on enhancing its presence in the overseas market, achieving a revenue of 355 million CNY from international operations, which is a 30.75% increase year-on-year [8]. - The strategic acquisition of stakes in sports brands and the expansion of the JD Outlet stores are part of the company's efforts to diversify and strengthen its market position [8].

Economic Overview - The global stock market has shown a slight recovery from April 30 to May 11, 2025, with technology stocks leading the gains[6] - The U.S. Treasury yields and the dollar have increased, while natural gas prices surged significantly, with Brent crude oil rising by 0.95%[9] - The market consensus indicates that trade negotiations are progressing positively, which has shaped the market rebound over the past month[6] Trade Negotiations - Recent U.S.-China trade talks resulted in a reduction of tariffs, with the overall tariff level on Chinese goods lowered to 30% (20% for fentanyl and 10% for general tariffs) and a temporary suspension of 24% tariffs for 90 days[22][23] - The outcome of these negotiations is expected to continue influencing market trends and could enhance the current market rebound's scope and sustainability[25] Economic Risks - There are significant risks related to the economic fundamentals, including potential downward trends in U.S. growth and inflationary pressures due to tariffs[27] - The U.S. economy is facing downward growth risks, with factors such as tariffs, immigration policies, and government layoffs contributing negatively[27] - Inflation risks are anticipated to rise, with tariff impacts potentially delaying inflationary effects by about two months[27] Employment Data - In April 2025, the U.S. non-farm payrolls increased by 177,000, significantly above the expected 138,000, with the unemployment rate stable at 4.2%[14] - Job growth was primarily driven by the service sector, while manufacturing and retail sectors showed declines[16] Market Sentiment - The market is currently in a phase where it may revert to trading based on economic fundamentals rather than trade negotiations, as existing policies have observable impacts on the economy[26] - The Federal Reserve's recent decision to maintain interest rates at 4.25%-4.50% reflects a cautious outlook on the economy amid ongoing trade tensions[19] Future Outlook - The timing and pace of any shift back to a fundamental trading paradigm remain uncertain, as the current environment is influenced by tariff negotiations and their implications for U.S. economic growth[28] - The U.S. must capitalize on the current risk window to finalize favorable trade outcomes and leverage opportunities for monetary policy easing[28]